Illumina, Inc. $ILMN Shares Acquired by PensionDanmark Pensionsforsikringsaktieselskab

PensionDanmark Pensionsforsikringsaktieselskab grew its position in Illumina, Inc. (NASDAQ:ILMN) by 9.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,664 shares of the life sciences company’s stock after purchasing an additional 3,100 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Illumina were worth $6,622,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ILMN. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter worth approximately $25,000. Creative Capital Management Investments LLC raised its stake in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new position in Illumina during the 4th quarter worth $26,000. Laurel Wealth Advisors LLC acquired a new position in Illumina during the 4th quarter worth $26,000. Finally, Activest Wealth Management grew its stake in shares of Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina to Rank #1, or “Strong Buy,” citing improving earnings prospects and strong momentum characteristics. The upgrade could attract near-term buying interest. What Makes Illumina a New Strong Buy Stock
• Positive Sentiment: Illumina’s latest quarterly results provide a supportive backdrop: earnings per share exceeded estimates, revenue topped forecasts, and sales increased 9.4% year over year. The company continues to guide to fiscal 2026 EPS of $5.30 to $5.40. Recent bullish analysts have raised price targets as high as $230. Illumina Earnings and Analyst Information
• Neutral Sentiment: Analyst opinion remains divided. Although several firms maintain Buy or Outperform ratings, the consensus rating is “Hold,” with an average price target of $188.40—close to recent trading levels—suggesting limited consensus upside.
• Negative Sentiment: Director Keith A. Meister sold 741,127 shares across August 4 and 5 for approximately $148.2 million, reducing his position by about 28%. He retains more than 2 million shares, but the size of the transactions may pressure sentiment and raise concerns about insider confidence. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated its “Sell” rating and $140 price target, arguing that a one-time consumables benefit may be masking weak underlying demand. The target is well below recent levels, highlighting valuation and sustainability concerns. Bank of America Maintains Sell Rating

Analyst Ratings Changes

A number of research analysts have recently commented on ILMN shares. Zacks Research raised Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Citigroup raised their target price on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Price Performance

Shares of Illumina stock opened at $187.96 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The company’s 50-day moving average price is $181.13 and its two-hundred day moving average price is $149.05. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00. The stock has a market cap of $28.38 billion, a PE ratio of 35.07, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Keith A. Meister sold 457,858 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,744,811 shares of company stock worth $303,897,291 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.